Gould Gregory A 4

4 · CytoDyn Inc. · Filed Nov 19, 2018

Insider Transaction Report

Form 4

Period: 2018-11-16

CytoDyn Inc.CYDY

GOULD GREGORY A

Director

Transactions

Award
Stock Options (right to buy)
2018-11-16+160,662→ 160,662 total
Exercise: $0.56From: 2018-02-07Exp: 2028-02-07→ Common Stock (160,662 underlying)
Award
Stock Options (right to buy)
2018-11-16+50,000→ 50,000 total
Exercise: $0.80From: 2018-02-15Exp: 2023-02-15→ Common Stock (50,000 underlying)
Award
Stock Options (right to buy)
2018-11-16+25,000→ 25,000 total
Exercise: $1.55From: 2013-06-01Exp: 2022-06-01→ Common Stock (25,000 underlying)
Award
Stock Options (right to buy)
2018-11-16+75,000→ 75,000 total
Exercise: $0.57From: 2018-09-01Exp: 2027-06-01→ Common Stock (75,000 underlying)
Award
Stock Options (right to buy)
2018-11-16+100,000→ 100,000 total
Exercise: $0.49Exp: 2028-06-08→ Common Stock (100,000 underlying)
Award
Common Stock
2018-11-16+19,176→ 19,176 total
Award
Stock Options (right to buy)
2018-11-16+50,000→ 50,000 total
Exercise: $0.66From: 2015-06-01Exp: 2019-06-01→ Common Stock (50,000 underlying)
Award
Stock Options (right to buy)
2018-11-16+50,000→ 50,000 total
Exercise: $2.00From: 2012-08-08Exp: 2021-08-08→ Common Stock (50,000 underlying)
Award
Stock Options (right to buy)
2018-11-16+50,000→ 50,000 total
Exercise: $0.97From: 2016-09-01Exp: 2025-06-01→ Common Stock (50,000 underlying)
Award
Stock Options (right to buy)
2018-11-16+50,000→ 50,000 total
Exercise: $1.09From: 2017-06-01Exp: 2026-06-01→ Common Stock (50,000 underlying)
Award
Stock Options (right to buy)
2018-11-16+100,000→ 100,000 total
Exercise: $0.68From: 2017-11-17Exp: 2026-11-17→ Common Stock (100,000 underlying)

Footnotes (3)

[F1]On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock.
[F2]In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance).
[F3]The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION